國家衛生研究院 NHRI:Item 3990099045/3006
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911190      Online Users : 935
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3006


    Title: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients
    Authors: Liu, JM;Chen, LT;Chao, Y;Li, AFY;Wu, CW;Liu, TS;Shiah, HS;Chang, JY;Chen, CT;Wu, HW;Lin, WC;Lan, C;Whang-Peng, J
    Contributors: National Institute of Cancer Research;Division of Biotechnology and Pharmaceutical Research
    Abstract: Purpose: A phase 11 and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m(2) as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 mug/ml,which was high compared to the mean peak drug concentration of 6 +/- 4.1 mug/ml. The mean systemic GL331 clearance was 12.1 +/- 7.2 l/h per m(2), much lower than 23.3 +/- 8.2 l/h per m(2) found in the phase I trial. Topoisomerase IIalpha was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.
    Keywords: Oncology;Pharmacology & Pharmacy
    Date: 2002-05
    Relation: Cancer Chemotherapy and Pharmacology. 2002 May;49(5):425-428.
    Link to: http://dx.doi.org/10.1007/s00280-002-0429-3
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0344-5704&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000176113700011
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036232644
    Appears in Collections:[Jacqueline Whang-Peng(1996-2007)] Periodical Articles
    [Chiung-Tong Chen] Periodical Articles
    [Ming Jacqueline Liu(1996-2007)] Periodical Articles
    [Her-Shyong Shiah(1996-2012)] Periodical Articles
    [Jang-Yang Chang] Periodical Articles
    [Li-Tzong Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    000176113700011.pdf75KbAdobe PDF727View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback